A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

Withdrawn before enrolling · Phase 2

Conditions studied: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung

In brief

The purpose of this study is to determine if EGFR status (positive or negative) by FISH can predict response to cetuximab therapy in NSCLC patients treated with carboplatin and paclitaxel

Key facts

Study ID
NCT00768131
Run by
Eli Lilly and Company
People needed
0
Starts
2008-10-01
Expected to finish
2008-10-01
Last updated by the study team
2015-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.